STOCKHOLM, SWEDEN / ACCESSWIRE / January 27, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical firm that develops a broad portfolio of small molecule drug candidates for illnesses affecting the central nervous system, with tasks in each Alzheimer’s illness and ache, at this time introduced that the corporate’s presentation and poster relating to the analysis platform in neurology, Alzstatin, as offered on the Eleventh Symposium on Pharmaceutical Profiling in Drug Discovery and Growth on January 27, 2022 in Uppsala, Sweden, at the moment are obtainable in its entirety on the corporate’s web site.
The poster, titled Growth of novel gamma-secretase modulators for the remedy of Alzheimer’s illness , was offered by Dr. Maria Backlund and incorporates new preclinical knowledge displaying potent results on amyloid manufacturing indicating that Alzstatin is a promising illness modifying and preventive remedy for the remedy of early Alzheimer’s illness.
The presentation included knowledge on the results of AC-0027875, a novel potent compound from the Alzstatin platform, on Aβ42 discount in cells and animals.
AC-0027875 effectively diminished Aβ42 manufacturing in cells and lowered Aβ42 within the mind in a time-dependent method. The compound additionally displayed good pharmacokinetic properties and additional research with the compound is at present in progress.
“Aggregation of poisonous amyloid beta, Aβ42, leads to amyloid plaque formation – a course of that performs a pivotal function in early Alzheimer’s illness pathogenesis. γ-Secretase modulators, so referred to as GSMs, characterize a promising class of Aβ42-lowering anti-amyloidogenic compounds that differentiates from antibody therapies and our compounds in Alzstatin are wonderful examples of that,” stated Martin Jönsson, CEO at AlzeCure Pharma.
The presentation, the poster and the summary can be found on AlzeCure’s web site: ( https://www.alzecurepharma.se/en/presentations-and-interviews/ ).
For extra data, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical firm that develops new modern drug therapies for the remedy of extreme illnesses and circumstances that have an effect on the central nervous system, corresponding to Alzheimer’s illness and ache – indications for which at present obtainable remedy may be very restricted. The corporate is listed on Nasdaq First North Premier Development Market and is growing a number of parallel drug candidates based mostly on three analysis platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates the place the distinctive mechanism of motion permits for a number of indications, together with Alzheimer’s illness, in addition to cognitive issues related to traumatic mind harm, sleep apnea and Parkinson’s illness. The Alzstatin platform focuses on growing disease-modifying and preventive drug candidates for early remedy of Alzheimer’s illness and includes two drug candidates. Painless is the corporate’s analysis platform within the discipline of ache and incorporates two tasks: ACD440, which is a drug candidate within the medical growth part for the remedy of neuropathic ache, and TrkA-NAM, which targets extreme ache in circumstances corresponding to osteoarthritis. AlzeCure goals to pursue its personal tasks via preclinical analysis and growth via an early medical part, and is frequently engaged on enterprise growth to search out appropriate outlicensing options with different pharmaceutical firms.
FNCA Sweden AB, +46(0)8 528 00 399 [email protected] , is the corporate’s Licensed Adviser. For extra data, please go to www.alzecurepharma.se .
AlzeCure’s disease-modifying analysis platform, Alzstatin, consisting of disease-modifying and preventive drug candidates, focuses on decreasing the manufacturing of poisonous amyloid beta (Aβ), corresponding to Aβ42, within the mind. Aβ42 performs a key pathological function in Alzheimer’s and begins to build up within the mind years earlier than clear signs develop. The drug candidates within the Alzstatin platform modulate the perform of the enzyme gamma secretase. Gamma secretase acts like a pair of scissors and cuts Aβ42 out from an extended protein referred to as APP. The sticky Aβ42 clumps collectively giving rise to the amyloid plaque so typical of Alzheimer’s illness. The candidates within the Alzstatin platform have an effect on enzyme perform in order that it as a substitute cuts out shorter types of the Aβ peptide, Aβ37 and Aβ38, which along with them not being sticky and never forming aggregates, even have a restrictive results on Aβ42 aggregates already shaped. This implies the drug candidates within the Alzstatin platform have two separate however synergistic results that collectively contribute to a stronger anti-amyloidogenic – and thus stronger – disease-modifying impact. This particular mechanism of motion differentiates it from organic therapies, e.g. antibodies. Furthermore, small molecules corresponding to Alzstatin, have a number of different benefits, together with straightforward and non-invasive administration as tablets or capsules. Small molecules may even usually move extra readily via the blood-brain barrier to achieve its goal, the mind.
Martin Jönsson CEO AlzeCure Pharma
Novel knowledge in Alzstatin Alzheimer’s undertaking offered on the Eleventh Pharmaceutical Profiling assembly
SOURCE: AlzeCure Pharma
View supply model on accesswire.com: